GlassScriptPhysician profile
Joseph Wandass
NPI 1760446884
$1,387.86
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $722 · 2021: $498 · 2022: $57.11.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $218.35 | 2020-2021 | |
| Amarin Pharma, INC. | $192.35 | 2019-2021 | |
| Lilly USA, LLC | $156.60 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.53 | 2020-2021 | |
| Abbvie INC. | $103.70 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $99.11 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $79.86 | 2019-2021 | |
| Allergan, INC. | $74.03 | 2020-2021 | |
| Esperion Therapeutics, INC. | $66.92 | 2021 | |
| Pfizer INC. | $48.67 | 2020-2021 | |
| Eisai INC. | $47.71 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.99 | 2019-2020 | |
| Glaxosmithkline, LLC. | $42.76 | 2019 | |
| Merck Sharp & Dohme LLC | $40.06 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $15.22 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Wandass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.